LACOG 0115 – LORELEI | A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer.
LACOG 0419 – NEOSAMBA | Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer OPEN FOR RECRUITMENT
LACOG 0715 – PALLAS | A randomized phase III trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer
LACOG 2118 – ALEXANDRA/IMpassion 030 | A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
LACOG 0218 – Hercules | A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer
LACOG 0519 – PEACE III | A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III
LACOG 0620 – ExBAT | Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)
LACOG 2018 – Foundation Penile | Molecular characterization of penile cancer in developing countries.
LACOG 0920 – Senticol III | International Validation Study Of Sentinel Node Biopsy In Early Cervical Cancer OPEN FOR RECRUITMENT
LACOG 1018 – PALBO in Ovarian Cancer | Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer
LACOG 0720 – SMART-KEY | SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers OPEN FOR RECRUITMENT
LACOG 2218 – PACIFIC BRAZIL | Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL) OPEN FOR RECRUITMENT
